EUVIMEDEUVIMED entdecken
Crossref

Synergistic role of gut-microbial L-ornithine in enhancing ustekinumab efficacy for Crohn’s disease

Zhenyu Wang, Li Tian, Yi Jiang, Lijun Ning, Xiaoqiang Zhu, Xuejie Chen, Baoqin Xuan, Yilu Zhou, Jinmei Ding, Yanru Ma, Ying Zhao, Xiaowen Huang und 7 weitere

Cell Metabolism · 2025-05 · 37 (5) · 1089-1102.e7

DOI: 10.1016/j.cmet.2025.01.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Metabolism, 2025-05. Verfasst von Zhenyu Wang und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, Renji Hospital, School of Medicine, Shanghai Jiao Tong Universi…. Hauptthemen laut MEDLINE: Crohn Disease, Gastrointestinal Microbiome, Ustekinumab, Ornithine. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: Natural Science Foundation of Shanghai Municipality, National Natural Science Foundation of China, Shanghai Municipal Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The role of the intestinal microbiome in Crohn's disease (CD) treatment remains poorly understood. This study investigates microbe-host interactions in CD patients undergoing ustekinumab (UST) therapy. Fecal metagenome, metabolome, and host transcriptome data from 85 CD patients were analyzed using multi-omics integration and mediation analysis. Our findings reveal significant microbiome-metabolite-host interactions. Specifically, Faecalibacterium prausnitzii was linked to altered L-ornithine biosynthesis, resulting in higher L-ornithine levels in patients before UST therapy. In vivo and in vitro studies demonstrated that microbiome-derived L-ornithine enhances UST treatment sensitivity in CD by disrupting the host IL-23 receptor signaling and inhibiting Th17 cell stabilization through the IL-12RB1/TYK2/STAT3 axis. L-ornithine significantly enhances the therapeutic efficacy of UST in CD patients, as demonstrated in a prospective clinical trial. These findings suggest that targeting specific microbe-host metabolic pathways may improve the efficacy of inflammatory bowel disease (IBD) treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseGastrointestinal MicrobiomeUstekinumabOrnithineHumansMaleFemaleAdultAnimalsMiceTh17 CellsMiddle AgedFaecalibacterium prausnitziiSignal TransductionTreatment OutcomeFecesReceptors, Interleukin

Stichwörter der Autor:innen

Crohn’ s diseaseEGR1Faecalibacterium prausnitziiIL-12/IL-23 signaling pathwayIL-12RB1L-ornithineTh17 cellmediation analysismulti-omicsustekinumab

Substanzen

UstekinumabOrnithineReceptors, Interleukin

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 145 Middle Shandong Road, Shanghai 200001, China.
  • Department of Gastroenterology, The Third Xiangya Hospital of Central South University, Changsha, China.
  • Department of Infectious Disease, Shanghai Children's Medical Center, National Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Dongfang Rd. 1678, Shanghai 200127, China.
  • Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 145 Middle Shandong Road, Shanghai 200001, China. Electronic addre…
  • Department of Gastroenterology, The Third Xiangya Hospital of Central South University, Changsha, China. Electronic address: wangxiaoyan@csu.edu.cn.

Förderung

  • Natural Science Foundation of Shanghai Municipality
  • National Natural Science Foundation of China
  • Shanghai Municipal Health Commission
  • Shanghai Municipal Education Commission

Zitieren

APA

Wang, Z., Tian, L., Jiang, Y., Ning, L., Zhu, X., Chen, X., Xuan, B., Zhou, Y., Ding, J., Ma, Y., Zhao, Y., Huang, X., Hu, M., Fang, J. Y., Shen, N., Cao, Z., Chen, H., Wang, X., & Hong, J. (2025). Synergistic role of gut-microbial L-ornithine in enhancing ustekinumab efficacy for Crohn’s disease. Cell Metabolism, 37(5), 1089-1102.e7. https://doi.org/10.1016/j.cmet.2025.01.007

Vancouver

Wang Z, Tian L, Jiang Y, Ning L, Zhu X, Chen X, et al. Synergistic role of gut-microbial L-ornithine in enhancing ustekinumab efficacy for Crohn’s disease. Cell Metabolism. 2025;37(5):1089-1102.e7. doi:10.1016/j.cmet.2025.01.007

BibTeX
@article{Wang2025,
  author = {Wang, Zhenyu and Tian, Li and Jiang, Yi and Ning, Lijun and Zhu, Xiaoqiang and Chen, Xuejie and Xuan, Baoqin and Zhou, Yilu and Ding, Jinmei and Ma, Yanru and Zhao, Ying and Huang, Xiaowen and Hu, Muni and Fang, Jing-Yuan and Shen, Nan and Cao, Zhijun and Chen, Haoyan and Wang, Xiaoyan and Hong, Jie},
  title = {Synergistic role of gut-microbial L-ornithine in enhancing ustekinumab efficacy for Crohn’s disease},
  journal = {Cell Metabolism},
  year = {2025},
  volume = {37},
  number = {5},
  pages = {1089--1102.e7},
  doi = {10.1016/j.cmet.2025.01.007}
}
Kostenlos starten →